Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS
0 意见
• 07/16/23
0
0
嵌入
Visit http://www.ecancer.org for more
Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) presents, at a press conference at ASCO 2015, a federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论